May 24

Pharma announces additional data from APF530 Phase 3 study on CINV A.

The ongoing firm presented the study results today at a poster display during the Multinational Association of Supportive Care in Tumor and the International Culture of Oral Oncology International Symposium in New York. As previously reported, the Phase 3 study showed APF530 was comparable to palonosetron in stopping both severe – and delayed-starting point CINV in patients getting either moderately emetogenic chemotherapy or highly emetogenic chemotherapy . Related StoriesOvarian cancer individuals with a history of oral contraceptive make use of have better outcomesStudy displays rare HER2 missense mutations do not spread breast cancer on the ownMeat-rich diet may boost kidney cancer risk ‘Delayed-onset nausea and vomiting remains a major issue associated with many cancer treatment options, which can influence a patient’s quality of life in addition to his or her ability to sustain the recommended potentially lifesaving chemotherapy regimen,’ said Rebecca A.Wurster/Susan Wurster Biel Bradley D. Anderson, Ph.D., may be the H.B. Kostenbauder Professor in Pharmaceutical Sciences at the University of Kentucky. His research is aimed at optimizing medication formulations and delivery systems to enable pharmaceutical items that are far better in dealing with disease. Many promising new drug molecules also exhibit unwanted physical or chemical properties that may hinder their advancement into useful items for patients.